Glioma incidence and survival variations by county‐level socioeconomic measures

Abstract

BACKGROUND: Multiple studies have reported higher rates of glioma in areas with higher socioeconomic status (SES) but to the authors' knowledge have not stratified by other factors, including race/ethnicity or urban versus rural location. METHODS: The authors identified the average annual age-adjusted incidence rates and calculated hazard ratios for death for gliomas of various subtypes, stratified by a county-level index for SES, race/ethnicity, US region, and rural versus urban status. RESULTS: Rates of glioma were highest in counties with higher SES (rate ratio, 1.18; 95% CI, 1.15-1.22 comparing the highest with the lowest quintiles [P < .001]). Stratified by race/ethnicity, higher rates in high SES counties persisted for white non-Hispanic individuals. Stratified by rural versus urban status, differences in incidence by SES were more pronounced among urban counties. Survival was higher for residents of high SES counties after adjustment for age and extent of surgical resection (hazard ratio, 0.82; 95% CI, 0.76-0.87 comparing the highest with the lowest quintile of SES [P < .001]). Survival was higher among white Hispanic, black, and Asian/Pacific Islander individuals compared with white non-Hispanic individuals, after adjustment for age, SES, and extent of surgical resection, and when restricted to those individuals with glioblastoma who received radiation and chemotherapy. CONCLUSIONS: The incidence of glioma was higher in US counties of high compared with low SES. These differences were most pronounced among white non-Hispanic individuals and white Hispanic individuals residing in urban areas. Better survival was observed in high SES counties, even when adjusting for extent of surgical resection, and when restricted to those who received radiation and chemotherapy for glioblastoma. Differences in incidence and survival were associated with SES and race, rather than rural versus urban status. Cancer 2019;125:3390-3400.

TRIB3 confers glioma cell stemness via interacting with β‐catenin

“…Although great progress in glioma treatment has been obtained in recent years, the results are still unsatisfactory and relapse happens in almost all patients . Cancer stem cells (CSCs) have been thought to be the root of tumor occurrence, metastasis, and recurrence .…”

Epidemiological Study of Malignant Gliomas in Korea Using Nationwide Dataset from 2007 to 2017

“…However, previous studies in the United States and Europe estimated statistically significant relative risks of glioma ranging from 1.1 to 1.2 when comparing high and low SES groups. 17 18 19 One study that analyzed race/ethnicity subtypes showed significantly lower incidence rates in Asia-Pacific countries of high SES compared with those of low SES. 19 High SES is associated with better access to treatment including surgery, chemotherapy, radiation, and other adjunctive options, which are associated with better survival rates.…”

“… 17 18 19 One study that analyzed race/ethnicity subtypes showed significantly lower incidence rates in Asia-Pacific countries of high SES compared with those of low SES. 19 High SES is associated with better access to treatment including surgery, chemotherapy, radiation, and other adjunctive options, which are associated with better survival rates. 20 21 In the present study, patients with low SES had less opportunity to undergo TMZ and operation and a higher risk of death compared with patients with high SES.…”

Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p

“…The main characteristics are diffuse invasive growth of tumor cells, unclear boundaries, relatively unlimited proliferation, and high invasiveness, all of which seriously affect human health 3 . Despite advances in the treatment of gliomas, the 5-year survival rate of glioma patients remains low 4 . For advanced glioma patients, systemic chemotherapy is main form of treatment 5 .…”